Narayan discusses what he thinks the future of nadofaragene firadenovec and bladder cancer are at this year’s SUO Meeting.
Vikram Narayan, MD, built off of his research at the 21st Annual Meeting of the Society of Urologic Oncology in an interview with CancerNetwork discussing the potential future of nadofaragene firadenovec and the field of bladder cancer.
I think this is a very promising time for patients with bladder cancer, and in particular patients with non-muscle invasive bladder cancer who have failed BCG. When I was a resident in training, I was always struck by how few options we had to offer these patients and fortunately this is something that’s starting to change, and it’s exciting that nadofaragene may be 1 potential option for these patients in the future. There’s still a lot of work that needs to be done, but some of the discussion at SUO was trying to identify ways and sort of develop plans to study biomarkers and other tools to identify which patients will most likely not only do best with certain treatments but potentially even look at combination strategies. And then we’ll also need to study what sequence of treatments, especially as more of these agents become available. What combinations are best and in what order should they potentially be explored for these patients. Those are areas of ongoing research that will need to be delved into.